The Seoul Administrative Court has suspended the financial watchdog's disciplinary actions against Samsung BioLogics.
Last November, the biopharmaceutical arm of Samsung Group filed an administrative lawsuit against the country's financial regulator over its ruling on the firm's accounting violations.
Earlier in the same month, the Financial Services Commission ruled that Samsung BioLogics intentionally changed its accounting method to inflate the value of its affiliate called Samsung Bioepis in 2015.
The regulator ordered a fine of around seven-million U.S. dollars and recommended firing the firm's CEO.
02:19
Pyeongyang and Washington exchange war of words ahead of December deadline
01:55
02:22
02:15
00:28
02:43
02:26
01:37
